Chengdu Aupone Pharmaceutical Co., Ltd.

Aupone Pharma Group was established in 2001, is a comprehensive health enterprise integrating R&D, production of API and formulation, CRO and COMO services etc. It has a total of700 employees, covering an area of more than 350000 m2 with one R&D center and two API and form­ulation plants, and the annual sales amount is more than 150 million US dollars. It is one of the most growth-oriented and innovative pharmace­utical enterprises in China. Our company strictly implements direction of GMP by FDA, fondaparinux sodium has obtained the FDA registration No. MF038428. Our cur­rent AP ls and preparations occupy a leading position in the Chinese market both on quality and sales. Among them, cetirizine hydrochloride tab­lets, sertraline hydrochloride tablets, terbinafine hydrochloride tablets, ferrous succinate tablets, etc., have passed the consistency evaluation of generic drugs by CFDA, and won the bid of National Centralized Procurement of drugs. Our company has a R&D team of more than 100 people, mainly with doctoral and master's degrees, and maintains long-term cooperative relations with China's top pharmaceutical universities, such as Sichuan University. We have rich experiences on CRO, CDMO and OEM with est­eemed big pharmaceutical companies.